Find a job

Subscribe for free

All things Pharma

NICE recommends AstraZeneca’s ovarian cancer treatment  

The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s Lynparza (olaparib) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab, and whose cancer is associated with homologous recombination deficiency (HRD)-positive status1.

Ovarian cancer is the sixth most common cancer in the UK with 7,400 new diagnoses and 4,100 deaths each year. Around half of women with advanced high-grade ovarian cancer have HRD, when the body is unable to repair breaks in the DNA.

The decision from NICE is based on positive results from the PAOLA-1 Phase III trial, which showed that olaparib in combination with bevacizumab reduced the risk of death by 67% in the subgroup of patients with HRD-positive advanced ovarian cancer.

Tom Keith-Roach, President, AstraZeneca UK, said: “We are delighted with this recommendation for women with advanced (stage IIIB-IV) homologous recombination deficiency (HRD)-positive ovarian cancer. Olaparib was discovered and developed in England, and it is important that UK patients can routinely and rapidly access such medicines.”

David Brocklehurst, Head of Oncology, AstraZeneca UK, said: “Approximately 50% of women in the UK with advanced ovarian cancer have cancers that are homologous recombinant deficiency (HRD) positive. It is critical that routine HRD testing is provided by the NHS at the point of diagnosis to increase chances of accessing olaparib.”

Reference

1 National Institute for Health and Care Excellence. Olaparib with bevacizumab for maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Final Draft Guidance. Issue Date: 8 December 2023.

- Advertisement -
Emma Cooper
Emma Cooper
Emma is Content Manager of Pf Media.

MORE FROM AUTHOR

- Advertisement -

LATEST POSTS

Subscribe

Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription